BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a naturally occurring protein found in human gastric juice. First isolated in the early 1990s, it has become one of the most widely discussed peptides in the performance enhancement and biohacking communities.
Unlike many research compounds, BPC-157 has shown remarkable stability. It remains active in human gastric juice, does not require a carrier, and demonstrates resistance to degradation — properties that have led researchers to explore oral as well as injectable administration routes.
The compound has been studied extensively in animal models across a wide range of applications including tendon and ligament healing, gastrointestinal repair, neuroprotection, and even cardiovascular function. While human clinical trials remain limited, the breadth of preclinical data has made BPC-157 one of the most popular peptides among researchers and self-experimenters alike.
Why BPC-157 Stands Out
What makes BPC-157 unique among peptides is its versatility. Most peptides target a single pathway or receptor system. BPC-157, by contrast, appears to influence multiple healing mechanisms simultaneously — from upregulating growth hormone receptors to modulating the nitric oxide (NO) system and promoting angiogenesis (new blood vessel formation).
This multi-pathway activity may explain why user reports consistently describe benefits across such a wide range of conditions: from nagging joint injuries and gut issues to recovery from surgery and even cognitive improvements. The compound’s safety profile in animal studies has been exceptionally clean, with no reported LD50 (lethal dose) even at extremely high concentrations.
Looking for the best vendor deals?
Compare prices across 10+ peptide and anabolic vendors. Find the best quality at the lowest price.
Compare VendorsCurrent Research Landscape
As of 2026, BPC-157 remains classified as a research compound. It is not FDA-approved for any medical condition, and no completed Phase III clinical trials exist. However, several Phase I and Phase II trials are underway exploring its applications in inflammatory bowel disease and tendon repair.
The majority of published research comes from a single research group at the University of Zagreb, led by Dr. Predrag Sikiric. While the consistency and volume of their positive findings is notable, the scientific community has called for independent replication studies to strengthen the evidence base.
For the self-experimentation community, BPC-157 remains one of the most commonly used peptides, with a reputation for being well-tolerated and effective — particularly for musculoskeletal injuries and gut health optimization.